We are live on ! Find out more
ST

Skorpios Trust Portfolio holdings

AUM $53.2M
1-Year Est. Return 90.96%
This Fund
S&P 500
This Quarter Est. Return
-5.65%
1 Year Est. Return
+90.96%
3 Year Est. Return
+173.58%
5 Year Est. Return
10 Year Est. Return
AUM
$452M
AUM Growth
Cap. Flow
+$455M
Cap. Flow %
100.73%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.64%
2 Technology 0.32%
3 Miscellaneous 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STOK icon
1
Stoke Therapeutics
STOK
$2.1B
$347M 76.67%
+14,443,681
New +$345M
AKRO
2
DELISTED
Akero Therapeutics
AKRO
$104M 22.97%
+4,907,829
New +$109M
ATVI
3
DELISTED
Activision Blizzard
ATVI
$1.44M 0.32%
+21,600
New +$1.48M
XBI icon
4
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$189K 0.04%
+1,686
New +$203K
OGN icon
5
Organon & Co
OGN
$3.61B
$16K ﹤0.01%
+530
New +$17.3K

Similar funds

Skorpios Trust's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for Skorpios Trust, which disclosed 5 positions worth $452M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Stoke Therapeutics: 14,443,681 shares worth $347M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, followed by Technology and Miscellaneous.

  • Skorpios Trust's largest Q4 2021 buy was Stoke Therapeutics: 14,443,681 shares worth $347M.
  • Skorpios Trust's ten largest holdings make up 100% of its $452M portfolio in Q4 2021.
  • Skorpios Trust disclosed 5 positions in Q4 2021, its first 13F filing on record.

Based on Skorpios Trust's 13F filing for Q4 2021, filed 27 Jan 2022.